222 related articles for article (PubMed ID: 36131292)
21. Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue.
Brolin J; Skoog L; Ekman P
Prostate; 1992; 20(4):281-95. PubMed ID: 1376911
[TBL] [Abstract][Full Text] [Related]
22. Calcitonin and calcitonin gene-related peptide in the human prostate gland.
Abrahamsson PA; Dizeyi N; Alm P; di Sant'Agnese PA; Deftos LJ; Aumüller G
Prostate; 2000 Aug; 44(3):181-6. PubMed ID: 10906733
[TBL] [Abstract][Full Text] [Related]
23. Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia.
Cohen P; Peehl DM; Baker B; Liu F; Hintz RL; Rosenfeld RG
J Clin Endocrinol Metab; 1994 Nov; 79(5):1410-5. PubMed ID: 7525636
[TBL] [Abstract][Full Text] [Related]
24. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation.
Kramer G; Steiner GE; Handisurya A; Stix U; Haitel A; Knerer B; Gessl A; Lee C; Marberger M
Prostate; 2002 Jun; 52(1):43-58. PubMed ID: 11992619
[TBL] [Abstract][Full Text] [Related]
25. Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues.
Zhao H; Ramos CF; Brooks JD; Peehl DM
J Cell Physiol; 2007 Jan; 210(1):111-21. PubMed ID: 17044071
[TBL] [Abstract][Full Text] [Related]
26. Molecular profiling of benign prostatic hyperplasia using a large scale real-time reverse transcriptase-polymerase chain reaction approach.
Fromont G; Chene L; Latil A; Bieche I; Vidaud M; Vallancien G; Mangin P; Fournier G; Validire P; Cussenot O
J Urol; 2004 Oct; 172(4 Pt 1):1382-5. PubMed ID: 15371850
[TBL] [Abstract][Full Text] [Related]
27. Stem cell features of benign and malignant prostate epithelial cells.
De Marzo AM; Nelson WG; Meeker AK; Coffey DS
J Urol; 1998 Dec; 160(6 Pt 2):2381-92. PubMed ID: 9817389
[TBL] [Abstract][Full Text] [Related]
28. Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression.
Royuela M; de Miguel MP; Ruiz A; Fraile B; Arenas MI; Romo E; Paniagua R
Eur Cytokine Netw; 2000 Mar; 11(1):119-27. PubMed ID: 10705309
[TBL] [Abstract][Full Text] [Related]
29. Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment.
Nicholson TM; Sehgal PD; Drew SA; Huang W; Ricke WA
Differentiation; 2013; 85(4-5):140-9. PubMed ID: 23792768
[TBL] [Abstract][Full Text] [Related]
30. Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes.
Liu D; Shoag JE; Poliak D; Goueli RS; Ravikumar V; Redmond D; Vosoughi A; Fontugne J; Pan H; Lee D; Thomas D; Salari K; Wang Z; Romanel A; Te A; Lee R; Chughtai B; Olumi AF; Mosquera JM; Demichelis F; Elemento O; Rubin MA; Sboner A; Barbieri CE
Nat Commun; 2020 Apr; 11(1):1987. PubMed ID: 32332823
[TBL] [Abstract][Full Text] [Related]
31. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
32. De novo steroid biosynthesis in human prostate cell lines and biopsies.
Sakai M; Martinez-Arguelles DB; Aprikian AG; Magliocco AM; Papadopoulos V
Prostate; 2016 May; 76(6):575-87. PubMed ID: 26841972
[TBL] [Abstract][Full Text] [Related]
33. Alterations in the methylome of the stromal tumour microenvironment signal the presence and severity of prostate cancer.
Lawrence MG; Pidsley R; Niranjan B; Papargiris M; Pereira BA; Richards M; Teng L; Norden S; Ryan A; Frydenberg M; Stirzaker C; Taylor RA; Risbridger GP; Clark SJ
Clin Epigenetics; 2020 Mar; 12(1):48. PubMed ID: 32188493
[TBL] [Abstract][Full Text] [Related]
34. Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteins.
Partin AW; Briggman JV; Subong EN; Szaro R; Oreper A; Wiesbrock S; Meyer J; Coffey DS; Epstein JI
Urology; 1997 Nov; 50(5):800-8. PubMed ID: 9372899
[TBL] [Abstract][Full Text] [Related]
35. Promotion of epithelial hyperplasia by interleukin-8-CXCR axis in human prostate.
Smith DK; Hasanali SL; Wang J; Kallifatidis G; Morera DS; Jordan AR; Terris MK; Klaassen Z; Bollag R; Lokeshwar VB; Lokeshwar BL
Prostate; 2020 Sep; 80(12):938-949. PubMed ID: 32542667
[TBL] [Abstract][Full Text] [Related]
36. RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease.
Christoph F; König F; Lebentrau S; Jandrig B; Krause H; Strenziok R; Schostak M
World J Urol; 2018 Feb; 36(2):187-192. PubMed ID: 29204705
[TBL] [Abstract][Full Text] [Related]
37. Regulation of PDE5 expression in normal prostate, benign prostatic hyperplasia, and adenocarcinoma.
Bisegna C; Gravina GL; Pierconti F; Martini M; Larocca L; Rossi P; Grimaldi P; Dolci S; Di Stasi S; Jannini EA
Andrology; 2020 Mar; 8(2):427-433. PubMed ID: 31433119
[TBL] [Abstract][Full Text] [Related]
38. Histopathologic characterization of hereditary benign prostatic hyperplasia.
Doehring CB; Sanda MG; Partin AW; Sauvageot J; Juo H; Beaty TH; Epstein JI; Hill G; Walsh PC
Urology; 1996 Oct; 48(4):650-3. PubMed ID: 8886078
[TBL] [Abstract][Full Text] [Related]
39. Frequent 14-3-3 sigma promoter methylation in benign and malignant prostate lesions.
Henrique R; Jerónimo C; Hoque MO; Carvalho AL; Oliveira J; Teixeira MR; Lopes C; Sidransky D
DNA Cell Biol; 2005 Apr; 24(4):264-9. PubMed ID: 15812243
[TBL] [Abstract][Full Text] [Related]
40. FGF17 is an autocrine prostatic epithelial growth factor and is upregulated in benign prostatic hyperplasia.
Polnaszek N; Kwabi-Addo B; Wang J; Ittmann M
Prostate; 2004 Jun; 60(1):18-24. PubMed ID: 15129425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
